Vitamin D modulates systemic inflammation in patients with severe COVID-19
The ability of vitamin D (VitD) to modulate immune responses in the clinical setting of COVID-19 infection is not well investigated. This study aimed to evaluate the ability of VitD to attenuate inflammatory responses in patients with severe COVID-19. Blood samples and nasopharyngeal swabs were obta...
Gespeichert in:
| Veröffentlicht in: | Life sciences (1973) 2022-10, Vol.307, p.120909-120909, Article 120909 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 120909 |
|---|---|
| container_issue | |
| container_start_page | 120909 |
| container_title | Life sciences (1973) |
| container_volume | 307 |
| creator | Sharif-Askari, Fatemeh Saheb Hafezi, Shirin Sharif-Askari, Narjes Saheb Alsayed, Hawra Ali Hussain Mdkhana, Bushra Selvakumar, Balachandar Temsah, Mohamad-Hani Saddik, Basema Al Anouti, Fatme Halwani, Rabih |
| description | The ability of vitamin D (VitD) to modulate immune responses in the clinical setting of COVID-19 infection is not well investigated. This study aimed to evaluate the ability of VitD to attenuate inflammatory responses in patients with severe COVID-19.
Blood samples and nasopharyngeal swabs were obtained from patients with severe COVID-19 who had been treated (20 patients), or not (25 patients), with VitD, during their stay in the intensive care unit. Western blotting was used to evaluate the expressions of STAT3, JNK and AKT signaling pathways and ELISA was used to measure levels of IL-6, IL-17, and IL-1β in blood of these patients.
Reduced levels of STAT3, JNK and AKT pathways and lower levels of proinflammatory cytokines such as IL-6, IL-17, and IL-1β were observed in VitD treated patients (50,000 IU of cholecalciferol weekly for 3 weeks), and in vitro following treatment of poly I:C stimulated PBMCs with VitD (50 nM of calcitriol). Moreover, lower circulatory levels of these proinflammatory cytokines following treatment with VitD were associated with lower serum levels of COVID-19-related severity markers such as D-dimer and C-reactive proteins (P |
| doi_str_mv | 10.1016/j.lfs.2022.120909 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9398944</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0024320522006099</els_id><sourcerecordid>36028169</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-6414737d09c935c0c810f0057619c8f22b6ee640488ff85f25d28012d938ba283</originalsourceid><addsrcrecordid>eNp9kNtKAzEQhoMotlYfwBvZF9h1kuwhQRCk9VAp9EZ7G9JsYlP2UDZppW9vymrRG69mhpn_n5kPoWsMCQac366TyriEACEJJsCBn6AhZgWPIaf4FA0BSBpTAtkAXTi3BoAsK-g5GtAcCMM5H6LXhfWytk00ieq23FbSaxe5vfO6tiqyjalkXUtv2yYU0SZkuvEu-rR-FTm9052OxvPFdBJjfonOjKycvvqOI_T-9Pg2foln8-fp-GEWqxQzH-cpTgtalMAVp5kCxTCYcFmRY66YIWSZa52nkDJmDMsMyUrCAJOSU7aUhNERuu99N9tlrUsVDupkJTadrWW3F6204m-nsSvx0e4Ep5zxNA0GuDdQXetcp81Ri0EcwIq1CGDFAazowQbNze-lR8UPyTBw1w_o8PrO6k44FVgpXdpOKy_K1v5j_wVSroia</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Vitamin D modulates systemic inflammation in patients with severe COVID-19</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Sharif-Askari, Fatemeh Saheb ; Hafezi, Shirin ; Sharif-Askari, Narjes Saheb ; Alsayed, Hawra Ali Hussain ; Mdkhana, Bushra ; Selvakumar, Balachandar ; Temsah, Mohamad-Hani ; Saddik, Basema ; Al Anouti, Fatme ; Halwani, Rabih</creator><creatorcontrib>Sharif-Askari, Fatemeh Saheb ; Hafezi, Shirin ; Sharif-Askari, Narjes Saheb ; Alsayed, Hawra Ali Hussain ; Mdkhana, Bushra ; Selvakumar, Balachandar ; Temsah, Mohamad-Hani ; Saddik, Basema ; Al Anouti, Fatme ; Halwani, Rabih</creatorcontrib><description>The ability of vitamin D (VitD) to modulate immune responses in the clinical setting of COVID-19 infection is not well investigated. This study aimed to evaluate the ability of VitD to attenuate inflammatory responses in patients with severe COVID-19.
Blood samples and nasopharyngeal swabs were obtained from patients with severe COVID-19 who had been treated (20 patients), or not (25 patients), with VitD, during their stay in the intensive care unit. Western blotting was used to evaluate the expressions of STAT3, JNK and AKT signaling pathways and ELISA was used to measure levels of IL-6, IL-17, and IL-1β in blood of these patients.
Reduced levels of STAT3, JNK and AKT pathways and lower levels of proinflammatory cytokines such as IL-6, IL-17, and IL-1β were observed in VitD treated patients (50,000 IU of cholecalciferol weekly for 3 weeks), and in vitro following treatment of poly I:C stimulated PBMCs with VitD (50 nM of calcitriol). Moreover, lower circulatory levels of these proinflammatory cytokines following treatment with VitD were associated with lower serum levels of COVID-19-related severity markers such as D-dimer and C-reactive proteins (P < 0.001) which in overall resulted in shorter length of ICU stay for VitD treated compared to untreated patients (18 days for VitD treated vs. 28 days for VitD untreated; P = 0.01).
This study reveals that VitD plays immunomodulatory role during COVID-19 infection, which further emphasizes the importance of maintaining a normal level of this vitamin for the prevention of hyperinflammatory conditions associated with COVID-19.
[Display omitted]</description><identifier>ISSN: 0024-3205</identifier><identifier>EISSN: 1879-0631</identifier><identifier>DOI: 10.1016/j.lfs.2022.120909</identifier><identifier>PMID: 36028169</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Anti-inflammatory effects ; Calcitriol ; COVID-19 ; Cytokines ; Humans ; IL-17 ; IL-6 ; Inflammation ; Interleukin-17 ; Interleukin-6 ; Poly I ; Proto-Oncogene Proteins c-akt ; STAT3 ; Vitamin D ; Vitamin D - therapeutic use ; Vitamin D Deficiency - complications ; Vitamin D Deficiency - drug therapy ; Vitamins - pharmacology ; Vitamins - therapeutic use</subject><ispartof>Life sciences (1973), 2022-10, Vol.307, p.120909-120909, Article 120909</ispartof><rights>2022 Elsevier Inc.</rights><rights>Copyright © 2022 Elsevier Inc. All rights reserved.</rights><rights>2022 Elsevier Inc. All rights reserved. 2022 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-6414737d09c935c0c810f0057619c8f22b6ee640488ff85f25d28012d938ba283</citedby><cites>FETCH-LOGICAL-c418t-6414737d09c935c0c810f0057619c8f22b6ee640488ff85f25d28012d938ba283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0024320522006099$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36028169$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sharif-Askari, Fatemeh Saheb</creatorcontrib><creatorcontrib>Hafezi, Shirin</creatorcontrib><creatorcontrib>Sharif-Askari, Narjes Saheb</creatorcontrib><creatorcontrib>Alsayed, Hawra Ali Hussain</creatorcontrib><creatorcontrib>Mdkhana, Bushra</creatorcontrib><creatorcontrib>Selvakumar, Balachandar</creatorcontrib><creatorcontrib>Temsah, Mohamad-Hani</creatorcontrib><creatorcontrib>Saddik, Basema</creatorcontrib><creatorcontrib>Al Anouti, Fatme</creatorcontrib><creatorcontrib>Halwani, Rabih</creatorcontrib><title>Vitamin D modulates systemic inflammation in patients with severe COVID-19</title><title>Life sciences (1973)</title><addtitle>Life Sci</addtitle><description>The ability of vitamin D (VitD) to modulate immune responses in the clinical setting of COVID-19 infection is not well investigated. This study aimed to evaluate the ability of VitD to attenuate inflammatory responses in patients with severe COVID-19.
Blood samples and nasopharyngeal swabs were obtained from patients with severe COVID-19 who had been treated (20 patients), or not (25 patients), with VitD, during their stay in the intensive care unit. Western blotting was used to evaluate the expressions of STAT3, JNK and AKT signaling pathways and ELISA was used to measure levels of IL-6, IL-17, and IL-1β in blood of these patients.
Reduced levels of STAT3, JNK and AKT pathways and lower levels of proinflammatory cytokines such as IL-6, IL-17, and IL-1β were observed in VitD treated patients (50,000 IU of cholecalciferol weekly for 3 weeks), and in vitro following treatment of poly I:C stimulated PBMCs with VitD (50 nM of calcitriol). Moreover, lower circulatory levels of these proinflammatory cytokines following treatment with VitD were associated with lower serum levels of COVID-19-related severity markers such as D-dimer and C-reactive proteins (P < 0.001) which in overall resulted in shorter length of ICU stay for VitD treated compared to untreated patients (18 days for VitD treated vs. 28 days for VitD untreated; P = 0.01).
This study reveals that VitD plays immunomodulatory role during COVID-19 infection, which further emphasizes the importance of maintaining a normal level of this vitamin for the prevention of hyperinflammatory conditions associated with COVID-19.
[Display omitted]</description><subject>Anti-inflammatory effects</subject><subject>Calcitriol</subject><subject>COVID-19</subject><subject>Cytokines</subject><subject>Humans</subject><subject>IL-17</subject><subject>IL-6</subject><subject>Inflammation</subject><subject>Interleukin-17</subject><subject>Interleukin-6</subject><subject>Poly I</subject><subject>Proto-Oncogene Proteins c-akt</subject><subject>STAT3</subject><subject>Vitamin D</subject><subject>Vitamin D - therapeutic use</subject><subject>Vitamin D Deficiency - complications</subject><subject>Vitamin D Deficiency - drug therapy</subject><subject>Vitamins - pharmacology</subject><subject>Vitamins - therapeutic use</subject><issn>0024-3205</issn><issn>1879-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kNtKAzEQhoMotlYfwBvZF9h1kuwhQRCk9VAp9EZ7G9JsYlP2UDZppW9vymrRG69mhpn_n5kPoWsMCQac366TyriEACEJJsCBn6AhZgWPIaf4FA0BSBpTAtkAXTi3BoAsK-g5GtAcCMM5H6LXhfWytk00ieq23FbSaxe5vfO6tiqyjalkXUtv2yYU0SZkuvEu-rR-FTm9052OxvPFdBJjfonOjKycvvqOI_T-9Pg2foln8-fp-GEWqxQzH-cpTgtalMAVp5kCxTCYcFmRY66YIWSZa52nkDJmDMsMyUrCAJOSU7aUhNERuu99N9tlrUsVDupkJTadrWW3F6204m-nsSvx0e4Ep5zxNA0GuDdQXetcp81Ri0EcwIq1CGDFAazowQbNze-lR8UPyTBw1w_o8PrO6k44FVgpXdpOKy_K1v5j_wVSroia</recordid><startdate>20221015</startdate><enddate>20221015</enddate><creator>Sharif-Askari, Fatemeh Saheb</creator><creator>Hafezi, Shirin</creator><creator>Sharif-Askari, Narjes Saheb</creator><creator>Alsayed, Hawra Ali Hussain</creator><creator>Mdkhana, Bushra</creator><creator>Selvakumar, Balachandar</creator><creator>Temsah, Mohamad-Hani</creator><creator>Saddik, Basema</creator><creator>Al Anouti, Fatme</creator><creator>Halwani, Rabih</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20221015</creationdate><title>Vitamin D modulates systemic inflammation in patients with severe COVID-19</title><author>Sharif-Askari, Fatemeh Saheb ; Hafezi, Shirin ; Sharif-Askari, Narjes Saheb ; Alsayed, Hawra Ali Hussain ; Mdkhana, Bushra ; Selvakumar, Balachandar ; Temsah, Mohamad-Hani ; Saddik, Basema ; Al Anouti, Fatme ; Halwani, Rabih</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-6414737d09c935c0c810f0057619c8f22b6ee640488ff85f25d28012d938ba283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anti-inflammatory effects</topic><topic>Calcitriol</topic><topic>COVID-19</topic><topic>Cytokines</topic><topic>Humans</topic><topic>IL-17</topic><topic>IL-6</topic><topic>Inflammation</topic><topic>Interleukin-17</topic><topic>Interleukin-6</topic><topic>Poly I</topic><topic>Proto-Oncogene Proteins c-akt</topic><topic>STAT3</topic><topic>Vitamin D</topic><topic>Vitamin D - therapeutic use</topic><topic>Vitamin D Deficiency - complications</topic><topic>Vitamin D Deficiency - drug therapy</topic><topic>Vitamins - pharmacology</topic><topic>Vitamins - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sharif-Askari, Fatemeh Saheb</creatorcontrib><creatorcontrib>Hafezi, Shirin</creatorcontrib><creatorcontrib>Sharif-Askari, Narjes Saheb</creatorcontrib><creatorcontrib>Alsayed, Hawra Ali Hussain</creatorcontrib><creatorcontrib>Mdkhana, Bushra</creatorcontrib><creatorcontrib>Selvakumar, Balachandar</creatorcontrib><creatorcontrib>Temsah, Mohamad-Hani</creatorcontrib><creatorcontrib>Saddik, Basema</creatorcontrib><creatorcontrib>Al Anouti, Fatme</creatorcontrib><creatorcontrib>Halwani, Rabih</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Life sciences (1973)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sharif-Askari, Fatemeh Saheb</au><au>Hafezi, Shirin</au><au>Sharif-Askari, Narjes Saheb</au><au>Alsayed, Hawra Ali Hussain</au><au>Mdkhana, Bushra</au><au>Selvakumar, Balachandar</au><au>Temsah, Mohamad-Hani</au><au>Saddik, Basema</au><au>Al Anouti, Fatme</au><au>Halwani, Rabih</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vitamin D modulates systemic inflammation in patients with severe COVID-19</atitle><jtitle>Life sciences (1973)</jtitle><addtitle>Life Sci</addtitle><date>2022-10-15</date><risdate>2022</risdate><volume>307</volume><spage>120909</spage><epage>120909</epage><pages>120909-120909</pages><artnum>120909</artnum><issn>0024-3205</issn><eissn>1879-0631</eissn><abstract>The ability of vitamin D (VitD) to modulate immune responses in the clinical setting of COVID-19 infection is not well investigated. This study aimed to evaluate the ability of VitD to attenuate inflammatory responses in patients with severe COVID-19.
Blood samples and nasopharyngeal swabs were obtained from patients with severe COVID-19 who had been treated (20 patients), or not (25 patients), with VitD, during their stay in the intensive care unit. Western blotting was used to evaluate the expressions of STAT3, JNK and AKT signaling pathways and ELISA was used to measure levels of IL-6, IL-17, and IL-1β in blood of these patients.
Reduced levels of STAT3, JNK and AKT pathways and lower levels of proinflammatory cytokines such as IL-6, IL-17, and IL-1β were observed in VitD treated patients (50,000 IU of cholecalciferol weekly for 3 weeks), and in vitro following treatment of poly I:C stimulated PBMCs with VitD (50 nM of calcitriol). Moreover, lower circulatory levels of these proinflammatory cytokines following treatment with VitD were associated with lower serum levels of COVID-19-related severity markers such as D-dimer and C-reactive proteins (P < 0.001) which in overall resulted in shorter length of ICU stay for VitD treated compared to untreated patients (18 days for VitD treated vs. 28 days for VitD untreated; P = 0.01).
This study reveals that VitD plays immunomodulatory role during COVID-19 infection, which further emphasizes the importance of maintaining a normal level of this vitamin for the prevention of hyperinflammatory conditions associated with COVID-19.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>36028169</pmid><doi>10.1016/j.lfs.2022.120909</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0024-3205 |
| ispartof | Life sciences (1973), 2022-10, Vol.307, p.120909-120909, Article 120909 |
| issn | 0024-3205 1879-0631 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9398944 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anti-inflammatory effects Calcitriol COVID-19 Cytokines Humans IL-17 IL-6 Inflammation Interleukin-17 Interleukin-6 Poly I Proto-Oncogene Proteins c-akt STAT3 Vitamin D Vitamin D - therapeutic use Vitamin D Deficiency - complications Vitamin D Deficiency - drug therapy Vitamins - pharmacology Vitamins - therapeutic use |
| title | Vitamin D modulates systemic inflammation in patients with severe COVID-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T08%3A38%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vitamin%20D%20modulates%20systemic%20inflammation%20in%20patients%20with%20severe%20COVID-19&rft.jtitle=Life%20sciences%20(1973)&rft.au=Sharif-Askari,%20Fatemeh%20Saheb&rft.date=2022-10-15&rft.volume=307&rft.spage=120909&rft.epage=120909&rft.pages=120909-120909&rft.artnum=120909&rft.issn=0024-3205&rft.eissn=1879-0631&rft_id=info:doi/10.1016/j.lfs.2022.120909&rft_dat=%3Cpubmed_cross%3E36028169%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36028169&rft_els_id=S0024320522006099&rfr_iscdi=true |